Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for DBV Technologies S.A. (DBVT : NSDQ)

• Company Description    DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $1.41 Daily Weekly Monthly 20 Day Moving Average: 643,988 shares Shares Outstanding: 122.27 (millions) Market Capitalization: $173.01 (millions) Beta: 2.16 52 Week High: $6.47 52 Week Low: $1.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.04% 17.17% 12 Week 8.85% 19.65% Year To Date -11.56% 9.20%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 177-181 AVENUE PIERRE BROSSOLETTE - MONTROUGE,I0 92120 FRA ph: 33-1-55-42-78-78 fax: 33-1-43-26-10-83 anne.pollak@dbv-technologies.com http://www.dbv-technologies.com

• General Corporate Information    Officers Daniel Tasse - Chief Executive Officer Sebastien Robitaille - Chief Financial Officer Michel de Rosen - Director Mailys Ferrere - Director Michael J. Goller - Director Peer Information DBV Technologies S.A. (CORR.) DBV Technologies S.A. (RSPI) DBV Technologies S.A. (CGXP) DBV Technologies S.A. (BGEN) DBV Technologies S.A. (GTBP) DBV Technologies S.A. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23306J101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/01/22 Share - Related Items Shares Outstanding: 122.27 Most Recent Split Date: (:1) Beta: 2.16 Market Capitalization: $173.01 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.11 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 44.44% vs. Previous Quarter: -15.38% Sales Growth vs. Year Ago Period: -13.43% vs. Previous Quarter: -13.17% ROE 03/31/22 - -77.11 12/31/21 - -74.05 09/30/21 - - ROA 03/31/22 - -53.52 12/31/21 - -52.90 09/30/21 - - Current Ratio 03/31/22 - 3.47 12/31/21 - 3.64 09/30/21 - 3.26 Quick Ratio 03/31/22 - 3.47 12/31/21 - 3.64 09/30/21 - 3.26 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -1,607.17 12/31/21 - -1,720.20 09/30/21 - - Book Value 03/31/22 - 0.67 12/31/21 - 0.90 09/30/21 - 1.06 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©